Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03532971 · ClinicalTrials.gov registry record
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 100
- Enrollment target
NCT03532971: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT03532971 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03532971 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This research study is evaluating the reactivation of BK virus in patients who have undergone allogeneic hematopoietic-cell transplantation.
Interventions
- OTHER Symptom index questionnaire
- DIAGNOSTIC_TEST BK polyomavirus PCR
- OTHER quality of life questionnaires
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2020-09-14 |
What the finished NCT03532971 record still lists
NCT03532971 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Symptom index questionnaire is the first listed.
NCT03532971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03532971 about?
NCT03532971 is a clinical study titled "Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes". This research study is evaluating the reactivation of BK virus in patients who have undergone allogeneic hematopoietic-cell transplantation.
What is the current status of trial NCT03532971?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2018-07-30. Estimated completion is 2020-09-14.
What interventions are being tested in trial NCT03532971?
The interventions under investigation include: Symptom index questionnaire (OTHER), BK polyomavirus PCR (DIAGNOSTIC_TEST), quality of life questionnaires (OTHER).
Who is sponsoring clinical trial NCT03532971?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI